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ABSTRACT 
Starburst dendrimer, a structurally defined, spherical macromolecule composed of repeating polyamidoamino 
subunits, was investigated to augment plasmid-mediated gene transfer efficiency in a murine cardiac trans-
plantation model. The grafts were directly injected with naked pCHllO, a plasmid encoding /3-galactosidase 
(/8-Gal), or pCHllO-dendrimer complex, and reporter gene expression determined by X-Gal staining. The 
grafts injected with pCHllO-dendrimer demonstrated widespread and extended /3-Gal expression in both my-
ocytes and the graft infiltrating cells from 7 to 28 days, compared to the grafts injected with naked pCHllO 
that expressed /8-Gal only in myocytes for less than 14 days. paMHC-vIL-10, as plasmid encoding viral in-
terleukin-10 (vIL-10) under the control of a-myosin heavy chain promoter, was able to prolong allograft sur-
vival from 13.9 ± 0.9 days to 21.4 ± 2.3 days (p < 0.005). W h e n dendrimer G 5 E D A was used with p a M H C -
vIL-10, 60-fold less D N A resulted in significant prolongation of graft survival to 38.6 ± 4.7 days (p < 0.0005). 
The dose of D N A , the charge ratio of D N A to dendrimer, and the size generation of the dendrimers were all 
determined to be critical variables for prolongation of allograft survival in this model system. Thus, the use 
of the Starburst dendrimer dramatically increased the efficiency of plasmid-mediated gene transfer and ex-
pression. Production of immunosuppressive cytokines at higher amounts for longer periods of time in a greater 
expanse of tissue enhanced the immunosuppressive effect and prolonged graft survival further. 
OVERVIEW SUMMARY 
Plasmid-mediated gene therapy has been used to deliver im-
munosuppressive molecules into allografts to prolong graft 
survival. However, direct injection of naked plasmid D N A 
is inefficient because transgene expression is low and tran-
sient. This study investigated the ability of Starburst den-
drimers to augment plasmid-mediated gene transfer effi-
ciency in a murine cardiac transplantation model. The 
results demonstrate that dendrimers increased the effi-
ciency of transfer and expression of exogenous D N A in car-
diac grafts. Improved expression of an immunosuppressive 
cytokine viral interleukin-10 (vIL-10) by dendrimers sig-
nificantly prolonged allograft survival. The dose of DNA, 
the charge ratio of D N A to dendrimer, and the size gener-
ation of the dendrimers were all critical for prolongation of 
allograft survival. Thus, the use of the Starburst dendrimer 
as a carrier molecule for plasmid-mediated gene transfer 
improved the efficiency of transfer and expression, provid-
ing further therapeutic value for treatment of cardiac allo-
graft rejection. 
INTRODUCTION 
PREVIOUS STUDIES HAVE SHOWN that a Variety of plasmid and 
viral (retrovkus, herpesvirus, adenovirus) vectors can in-
troduce and express exogenous nucleic apids in isografts and 
allografts (Gainer et al, 1997; Efrat et al, 1995; Qin et al, 
1995; Bengamou et al, 1996; Drazan et al, 1996; Knetchle et 
al, 1996; Levy and Alexander, 1996) and prolong allograft sur-
vival by inhibiting alloantigen-specific immunity (Qin et al, 
1996a,b). Despite these successes, indefinite graft survival and 
tolerance have not yet been achieved. This is likely due to the 
fact that gene transfer is inefficient and expression is low and 
transient (Wolff ef a/., 1990; Jiao etal, 1992; Qin etal, 1995). 
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Attempts to improve the transfection efficiency with high-
titered viral vectors have met with limited success because of 
virus specific toxicities and antiviral immune responses (Bram-
son et al, 1995; Gordon and Anderson, 1994; Yang et al, 
1994). It is likely that plasmid D N A , which does not present 
these difficulties and is easily manipulated and purified, will be 
the preferred vector system used in clinical transplantation. 
However, the physical transfer of naked D N A into target cells 
is currentiy inefficient (Wolff et al, 1990; Jiao et al, 1992; Qin 
et al, 1994, 1995). Improved efficacy of plasmid gene transfer 
will therefore be required to deliver more effective immuno-
suppression and induce tolerance. 
Starburst polyamidoamine ( P A M A M ) dendrimers are a new 
class of highly branched spherical polymers that contain large 
numbers of amino groups on the surface (Tomalia and Durst, 
1993; Frechet, 1994), which are positively charged at physio-
logical pH. Dendrimers have been reliably produced in large 
quantities with several structural characteristics of the molecule 
(including the overall shape, density, and surface charge) syn-
thesized precisely (Tomalia and Durst, 1993; Frechet, 1994). 
The defined structure and large number of surface amino groups 
of P A M A M dendrimers make them good polycations to inter-
act with biologically relevant polyanions, including nucleic 
acids. P A M A M dendrimers have been used as a substrate for 
the attachment of antibodies, contrast agents, and radiophar-
maceuticals for applications in a number of different areas of 
biology and medicine both in vitro and in vivo (Roberts et al, 
1990; Barth et al, 1994; Singh et al, 1994), and shown to be 
nontoxic and able to target biologic agents to specific cells 
(Roberts et al, 1990; Barth et al, 1994; Singh et al, 1994). 
Recent studies demonstrated that P A M A M dendrimers can 
form stable complexes with plasmids and oligonucleotides that 
dramatically enhance gene transfer and expression in a variety 
of mammalian cell lines in vitro (Bielinska et al, 1996; 
Kukowska-Latallo et al, 1996). The stability of DNA/den-
drimer complexes and high transfection efficiency with mini-
mal cytotoxicity suggest that this transfection method has the 
potential for in vivo applications. This study investigated the 
abUity of dendrimers to augment plasmid-mediated gene trans-
fer efficiency in a murine cardiac transplantation model. 
Interleukin-10 was originally termed cytokine synthesis in-
hibitory factor (Moore et al, 1990) and is able to regulate a va-
riety of immune responses negatively (Hsu etal, 1990; de Waal 
Malefyt et al, 1991a,b; Del et al, 1993; Enk et al, 1993; 
Peguet-Navarro et al, 1994; Qin et al, 1996a), such as inhibi-
tion of the synthesis of cytokines by ThI cells, particularly in-
terferon-y (IFN-y); down-regulation of class II M H C expres-
sion on monocytes; and inhibition of the production of 
monokines, such as interleukin-1 (IL-1), IL-6, IL-8, IL-12, tu-
mor necrosis factor-a (TNF-a), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), and G-CSF. Viral IL-10, 
a product encoded by Epstein-Barr virus, is highly homologous 
to both murine and human IL-10, and shares many immunoin-
hibitory properties with murine and human IL-10, but does not 
possess the T cell co-stimulatory activities of authentic cellu-
lar IL-10 (Moore et al, 1990; de Waal Malefyt et al, 1991a,b; 
Hsu et al, 1990). Previous studies have shown that gene trans-
fer of vIL-10 by retroviral vectors prolonged allograft survival 
without systemic immunosuppression (Qin etal, 1996a). In this 
study, vIL-10 was used as an immunosuppressant to determine 
whether enhanced transfer of the c D N A for this cytokine by 
dendrimer could achieve an improved therapeutic effect. 
MATERIALS AND METHODS 
Mice 
CBA/J (H-2'') and C57BL/6J (H-2'') female mice (8-10 
weeks of age) were purchased from The Jackson Laboratory 
(Bar Harbor, M E ) . Timed pregnant C57BL/6 mice were pur-
chased from Harlan-Sprague-Dawley, Inc. (Indianapolis, IN). 
Plasmids 
pCHl 10 (Hall et al, 1983), encoding the j3-galactosidase (/3-
Gal) gene under the control of the simian virus 40 (SV40) pro-
moter; and p M C 1871 (Shapiraera/., 1983), a promoterless plas-
mid encoding ;S-Gal, were used. pRaMHCluc (Kitsis et al, 
1991), consisting of the firefly luciferase c D N A attached to rat 
a-cardiac myosin heavy chain ( a M H C ) 5'-flanking sequences 
(-613 to -1-32, relative to the start of transcription); and 
pH/3MHCluc (Yamauchi-Takihara et al, 1989), consisting of 
the firefly luciferase c D N A attached to human ̂ -myosin heavy 
chain ()3MHC) 5'-flanking sequences (—1,232 to -1-28, relative 
to the start of transcription), were provided by Dr. L. Leinwand 
(Albert Einstein College of Medicine). pcD-SRa-vIL-10 
(Takebe et al, 1988), encoding vIL-10 gene under the control 
of SR alpha promoter, was provided by Dr. H. Tahara (Uni-
versity of Pittsburgh). paMHC-vBL-lO, encoding vIL-10 under 
the control of a M H C promoter, was constructed by introduc-
tion of 0.6 kb of vIL-lO c D N A from pcD-SRa-vIL-10 into die 
Xho I site of pRaMHCluc from which firefly luciferase c D N A 
was removed by Bgl ll-Ppu M I digestion and blunt end liga-
tion; p/3MHCvIL-10, a plasmid encoding vIL-10 under the con-
trol of /3MHC promoter, was constructed using same strategy 
but vIL-10 c D N A introduced into pH/3MHCluc. All plasmids 
were purified by two cycles of CsCl gradient centrifugation. 
Dendrimer 
Starburst PAMAM dendrimers were synthesized and pre-
pared as previously described (Tomalia and Durst, 1993; Bielin-
ska et al, 1996; Kukowska-Latallo et al, 1996). The fifth and 
ninth generation of ethylenediamine (EDA) core dendrimer 
(G5EDA and G 9 E D A , respectively) (Tomalia and Durst, 1993; 
Bielinska et al, 1996; Kukowska-Latallo et al, 1996) were 
tested in this study. The DNA-dendrimer complexes were pre-
pared by adding 0.31 pg of D N A plus 10.10 pg dendrimer in 
a total volume of 5 pi in phosphate-buffered saline (PBS), 
which makes a D N A : dendrimer charge ratio of 1: 50 (Bielin-
ska et al, 1996; Kukowska-Latallo et al, 1996), and incubated 
for at least 10 min at room temperature to allow complex for-
mation. Charge ratios in the range of 1:10 to 1:100 were also 
prepared using constant amounts of D N A and varying the den-
drimer concentration. 
Antibody 
The JES3-19F1.1 rat anti-human IL-10 (Bacchetta et al, 
1994) hybridoma was purchased from the A T C C (Rockville, 
M D ) , grown in culture, and purified over protein G columns 
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(Pharmacia-LKB, Piscataway, NJ). This antibody binds both 
human and viral IL-10. 
Cardiac transplantation 
The heterotopic, nonvascularized cardiac transplantation 
model was used. Briefly, donor neonatal C57BL/6 or CBA/J 
mice were sacrificed, and whole hearts removed and placed sub-
cutaneously in the ear pinnae of CBA/J recipients, as previously 
described (Qin et al, 1994, 1995, 1996a,b). The DNA-den-
drimer complexes were prepared as described above. Twenty 
micrograms of naked plasmid D N A in 5 p\ of P B S / 5 % sucrose 
or 5 pi of DNA-dendrimer complex were directly injected into 
the graft at the time of transplantation. JES3-19F1.1 m A b in 
0.5-ml volumes in P B S was injected intravenously at 100 pg 
every other day for six doses. Survival of cardiac allografts was 
followed with E K G monitoring (Polygraph 78 Series with pre-
amp and filters. Grass Instruments, Quincy, M A ) every other 
day. Cessation of cardiac electrical activity was taken as the de-
terminant of rejection. There were at least 5 mice per group. 
Statistical comparison was performed with the Student's Mest. 
For histologic studies, ears with transplanted hearts were ob-
tained, frozen, and sectioned at 10 p m for /3-Gal determination. 
X-Gal staining 
The ears with transplanted hearts were quick frozen, em-
bedded in O.C.T. (Miles Scientific, Naperville, IL), sectioned 
at 10 p m , collected onto gelatin-coated glass slides, fixed at 
room temperature in 0.25% glutaraldehyde in phosphate 
buffered saline (PBS) for 30 min, rinsed three times in P B S for 
a total of 30 min, and incubated at 37°C ovemight in X-Gal so-
lution containing 0.5 mg/ml of 5-bromo-4-chloro-3-indolyl-^-
D-galactopyranoside (X-Gal), 5 m.M potassium ferrocyanide, 5 
m M potassium ferricyanide, 2 m M M g C L , 1 m M spermidine, 
0.02% Nonidet P-40, and 0.01% sodium deoxycholate in PBS. 
After staining, the sections were fixed with 4 % formaldehyde 
and counterstained with eosin (Qin et al, 1995). 
RESULTS 
Dendrimer G5EDA increases the efficiency of plasmid 
gene transfer in vivo 
The charge ratio of DNA to dendrimer is one of the critical 
parameters in the optimization of in vitro transfection (Bielin-
ska et al, 1996; Kukowska-Latallo et al, 1996). The optimal 
charge ratio of D N A to dendrimer was selected through in vitro 
cytotoxicity and transfection studies of myocyte cell lines. The 
highest degree of in vitro transfection without toxicity was 
found at a D N A to dendrimer charge ratio of 1: 50 (not shown). 
Hence this charge ratio was used for initial in vivo studies. 
Donor hearts from neonatal C57BL/6 mice were transplanted 
to syngeneic recipients and injected with naked plasmids or 
plasmid-dendrimer complexes, and reporter gene expression 
was determined by X-Gal staining. The grafts injected with 
p C H l 10-dendrimer complex demonstrated widespread and ex-
tended /3-Gal expression (Fig. IB). The high-level expression 
lasted for at least 14 days after gene transfer, with significant 
numbers of the cells stained positively by X-Gal (Fig. IB and 
rT-T. T f T ! " ^ * ^ ; > ~ /• »«r». 
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FIG. 1. Dendrimer G 5 E D A enhances plasmid transfer of /3-
Gal genes to cardiac isografts in vivo. Donor neonatal C57BL/6 
mouse hearts were directiy injected with naked plasmid (20 pg 
of D N A ) or plasmid-dendrimer complex (0.31 p g D N A ) and 
transplanted into syngeneic recipients. The hearts were har-
vested 7 or 14 days later and stained with X-Gal for /3-Gal ac-
tivity. A. p C H l 10 alone, 7 days after transplantation. B and C. 
p C H 1 1 0 - G 5 E D A , 14 days after transplantation. Original mag-
nification, lOOX (A and B) and 400X (C). In C, arrows point 
to graft-infiltrating cells whereas other cells all appear to be 
myocytes. These sections are representative of at least three 
grafts for each group at each time point. 
Table 1). Reporter gene expression was dramatically decreased 
by 21 days, and only a few cells were still positive at day 28. 
Histologic studies demonstrated that both myocytes and the 
graft infiltrating cells were able to take up dendrimer-plasmid 
complex and express the transferred gene (Fig. IC). The sec-
tions prepared from the grafts injected with the same amount 
of naked pCHllO (0.31 pg) displayed no ;8-Gal activity, 
whereas injection of a 60-fold higher amount of naked p C H l 10 
(20 pg) resulted in only sparse j8-Gal expression at day 7 (Table 
1 and Fig. lA) that was localized to a very few cells staining 
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Table 1. Dendrimer G5EDA Enhances Reporter 
Gene Expression in Cardiac Isografts 
Days after transplantation 
and gene transfer 
Treatment D7 D14 D21 D28 
Untreated 
pMC1871 (20 ;u,g) 
pCH110(0.31 pg) 
pCH110(20 pg) 
pMC1871 (0.31 ;ag)-G5EDA 
pCH 110 (0.31 /Ag)-G5EDA -I--I--I- -I--I--I- -I--I-
Donor neonatal C57BL/6 mouse hearts were directiy injected 
with naked plasmid D N A (doses in parentheses) or 
plasmid-dendrimer complex (0.31 p g of plasmid and 10 p g of 
dendrimer G 5 E D A , which makes a D N A to dendrimer charge 
ratio of 1:50) and transplanted into syngeneic recipients. At 
various time points after transplantation, ears with transplanted 
hearts were obtained, frozen in O.C.T., sectioned at 10 p m , and 
stained with X-Gal for /3-Gal activity. + + + , Widespread cells 
stained blue; + + , many cells stained; +, few cells stained; -, 
none of the cells stained. There were at least three grafts for 
each group at each time point. At least 30 sections per graft 
were examined. 
positively. Only cells morphologically characteristic of myo-
cardial cells were stained blue after naked D N A transfer (Wolff 
et al, 1990; Jiao et al, 1992; Qin et al, 1994, 1995). T o rule 
out the possibility that endogenous ̂ -Gal was activated as a re-
sult of stimulation with dendrimer or plasmid-dendrimer com-
plex, a control plasmid p M C 1 8 7 1 was used. The results shown 
that p M C 1 8 7 1 , both naked and complexed with dendrimer, in-
duced no jS-Gal activity (Table 1). Dendrimers did not interfere 
with normal graft survival because syngeneic grafts injected 
with 10 ju,g of dendrimer G 5 E D A had indefinite survival up to 
150 days (not shown). Transplant recipients showed no appar-
ent toxic effects and no mortality associated with the use of 
dendrimers. Thus, use of dendrimer G 5 E D A as a carrier mol-
ecule dramatically increased the efficiency of transfer and ex-
pression of exogenous D N A in cardiac grafts. 
Dendrimer-enhanced gene transfer ofvIL-10 prolongs 
cardiac allograft survival 
Twenty micrograms of naked paMHC-vIL-10, a plasmid en-
coding vfl̂ -lO under the control of a M H C promoter, injected 
into allografts was able to prolong graft survival significantly 
from 13.9 ± 0.9 days to 21.4 ± 2.3 days (p < 0.005), whereas 
0.31 pg of naked D N A had no effect on graft survival. When 
dendrimer G 5 E D A was complexed witii paMHC-vIL-10 at a 
charge ratio of 1:50, 0.31 pg of D N A in a dendrimer complex, 
or 60-fold less than the optimal dose of naked D N A , resulted 
in even greater prolongation of graft survival to 38.6 ± 4.7 days 
(p < 0.005 vs untreated group, p < 0.025 vs 20 pg of naked 
paMHC-vIL-10 treated group) (Table 2). The prolongation of 
graft survival was dose-dependent, because lower doses of 
DNA-dendrimer enhanced graft survival less effectively (Table 
2). 
Because the charge ratio of D N A to dendrimer was a criti-
cal determinant in the optimization of in vitro transfection 
(Bielinska et al, 1996; Kukowska-Latallo et al, 1996), charge 
ratios in the range of 1:10 to 1:100 were also tested in vivo. The 
results in Table 2 demonstrate that a DNA-to-dendrimer 
G 5 E D A charge ratio of 1:50 was superior to eitiier 1:10 or 1:100 
in prolonging allograft survival m this model, which may re-
flect a higher transfection efficiency. 
To confirm that prolongation of graft survival was due to 
vIL-10 production, monoclonal anti-hIL-10 antibody JES3-
19F1.1, which cross-reacts with vIL-10 but not murine IL-10, 
was administered to the graft recipients. This treatment inhib-
ited the effects of paMHC-vIL-10-G5 administration (11.6 ± 
1.0 days, n = 5). Specificity was further confirmed using 
p/3MHCvIL-10, as plasmic encoding vIL-10 under the control 
of the /3MHC promoter. In the rodent, the /3-myosin heavy-
chain promoter is active in embryonic and fetal cardiac ventri-
cles, whereas the a-myosin heavy-chain promoter is active in 
postnatal and mature ventricles and in atria at all stages of de-
velopment and maturation (Rindt et al, 1993; Subramaniam et 
al, 1993). Thus, paMHC-vIL-10 should be able to dkect tiie 
transcription of vIL-10 in this model, whereas the p/3MHC-vIL-
10 should not be capable of directing vIL-10 transcription. As 
predicted, p^MHCvIL-10, both in naked form and complexed 
Table 2. paMHC-vIL-10-DENDRiMER G 5 E D A Prolongs Cardiac Allograft Survival: Dose and Charge Ratio 
paMHCvIL-10 
Treatment 
G5EDA Charge ratio 
Individual survival 
time (days) 
M S T ± SE 
(days) 
0.31 pg 
























14.0 ± 0.9 
13.6 ± 0.7 
21.4 ± 2.3* 
34.6 ± 4.6** 
18.8 ± 1.4 
16.0 ± 1.3 
24.2 ± 2.3 
19.2 ± 0.7 
*p < 0.005 versus untreated group. 
**p < 0.0005 versus untreated group, p < 0.025 versus 20 pg of naked paMHC-vIL-10-treated group. 
Donor neonatal C57BL/6 mouse hearts were injected directly with naked plasmid D N A or plasmid-dendrimer complex at die 
indicated doses and transplanted into CBA/J recipients. Survival of cardiac allografts was followed with E K G monitoring every 
other day. 
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witii G5EDA, had no effect on prolongation of allograft sur-
vival (14.0 ± 1.4 days (n = 5) and 13.2 ± 0.7 days (n = 10), 
respectively). These results demonstrate tiiat enhanced transfer 
of the cDNA for this cytokine by dendrimer could achieve an 
improved therapeutic effect. 
Dendrimer G5EDA is superior to G9EDA for 
prolongation of cardiac allograft survival 
Because dendrimers can be syntiiesized witii a defined num-
ber of rounds of repeating subunits, the optimal number of re-
peats or generations of dendrimer is different for ttansfecting 
different cell lines in vitro (Kukowska-Latallo et al, 1996). 
High generations of dendrimer demonsttated better transfection 
efficiencies for many cell lines (Kukowska-Latallo et al, 1996), 
thus we tested whether die ninth generation of dendrimer 
G9EDA could enhance vIL-10 gene ttansfer and prolong allo-
graft survival further compare to the fifth generation, G5EDA. 
The results in Table 3 demonsttate that when complexed witii 
G9EDA, paMHCvIL-10 significantiy prolonged allograft sur-
vival in a dose-dependent manner. DNA-to-dendrimer charge 
ratios from 1:10 to 1:50 were similar and superior to 1:100. 
Specificity was confirmed by administering anti-vIL-10 anti-
body JES3-19F1.1, which inhibited flie effects of paMHC-vIL-
10-G9EDA (from 24.6 ± 1.1 to 12.4 ± 0.7 days, n = 5). De-
spite having a slightiy higher ttansfection efficiency in die 
murine myoblast cell line C2C12 in vitro (note shown), G9EDA 
was not as effective as G 5 E D A in vivo for prolongation of graft 
survival (27.2 ± 1.7 days vs. 38.6 ± 4.7 days, p < 0.025). Be-
cause the microenvironment that dendrimer-DNA complexes 
encounter and/or the cell types that dendrimer-DNA complexes 
target in vivo are very different from those experienced in vitro, 
die data indicate that the optimal generation of dendrimer for 
an in vivo system needs to be empirically determined and is not 
fully predicted by prior in vitro modeling. 
DISCUSSION 
Previous studies showed that a variety of plasmid and viral 
(rettovinis, herpesvirus, adenovirus) vectors could successfully 
ttansfer reporter genes into murine cardiac grafts (Acsadi et al, 
1991; Wang etal, 1992,1996; Qin etal, 1994,1995,1996a,b, 
1997; Donahue et al, 1997), and the expression of immuno-
suppressive cytokines (vIL-10, mTGF/81) by rettoviral (Qin et 
al, 1995, 1996a), adenoviral (Qin et al, 1997), and plasmid 
vectors (Qin etal, 1994, 1995,1996b) prolonged allograft sur-
vival without systemic immunosuppression. The problem re-
mains that while allograft survival is prolonged, it is not in-
definite and tolerance has not been achieved. This is likely due 
in part to the fact that gene ttansfer is inefficient and expres-
sion is low and transient (Wolff et al, 1990; Jiao et al, 1992; 
Qin et al, 1994, 1995). Therefore, gains in allograft survival 
likely require improvements in gene ttansfer and expression so 
that immunosuppressive cytokines can be produced in higher 
amounts for longer periods of time. 
Cationic liposomes have been used to improve plasmid D N A 
delivery for various application of gene therapy (Nabel et al, 
1990; San et al, 1993; Feigner et al, 1995; Schofield and 
Caskey, 1995; Egilmez et al, 1996). Cationic liposomes bind 
polyanionic DNA; and by charge atttaction and fusion proper-
ties, the lipids can adsorb to the cell membrane and detiver the 
nucleic acid directiy into the cytoplasm, bypassing the lysoso-
mal degration pathway. Such liposomes are in widespread use 
as efficient means of ttansfecting plasmid D N A into a variety 
of cell lines grown in tissue culture. Several studies have shown 
the effectiveness of polycationic liposome delivery of D N A in 
vivo (Nabel et al, 1990; San et al, 1993; Feigner et al, 1995; 
Schofield and Caskey, 1995; Egilmez et al, 1996). However, 
most of the commercially available cationic lipids, including 
LipofectAMINE reagent, Lipofectin, Cellfectin, DC-Choles-
terol, and DMRIE-DOPE have a very poor ability to enhance 
D N A expression above the baseline achieved in vivo with naked 
D N A (Nabel et al, 1990; Feigner et al, 1995; Schofield and 
Caskey, 1995; Egilmez et al, 1996). Nabel et al reported diat 
fewer than 1% of cells were successfully ttansduced with a 
cationic liposome-DNA complex (Nabel et al, 1990). Egilmez 
et al. reported that the overall ttansfection efficiency of Lipo-
fectAMINE reagent, Lipofectin, Cellfectin, DC-Cholesterol, 
and DMRIE-DOPE did not exceed 0.3% in a tumor model, even 
under optimal conditions (Egilmez et al, 1996). Feigner et al. 
enhanced C A T expression in mouse lung with DLRIE only 25-
fold above the naked D N A level (Feigner et al, 1995). San et 
al. increased cationic liposome dose by 1,000-fold but only en-
hanced ttansfection efficiency of DMRIE/DOPE by 2- to 7-fold 
compared to DC-chol/DOPE (San et al, 1993). hi our cardiac 
model, attempts to use Lipofectin did not enhance plasmid in-
duced prolongation of allograft survival compared to naked 
D N A alone (not shown). . 
Starburst P A M A M dendrimers are a new class of branched 


























16 X 4,18 
M S T ± SE 
(days) 
24.6 ± 1.1* 
18.4 ± 1.1 
15.2 ± 1.2 
27.2 ± 1.7* 
16.4 ± 0.4 
*p < 0.005 versus untteated group. 
Donor neonatal C57BL/6 mouse hearts were directiy injected witii plasmid-dendrimer G9EDA complex at the indicated doses 
and ttansplanted into CBA/J recipients. Survival of cardiac allografts was followed with E K G monitoring every other day. 
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spherical polymers that have a unique surface of primary amino 
groups (Tomalia and Durst, 1993; Frechet, 1994), which show 
positive charge densities restricted to the surface of the mole-
cule. These characteristics allow dendrimers to interact simul-
taneously with both negatively charged phospholipids on cell 
membranes and D N A . Previous studies demonsttated that 
DNA-dendrimer complexes were stable for many weeks in so-
lution and capable of mediating high-efficiency transfection to 
a variety of cell lines, including primary cells and nonadherent 
cell lines in vitro (Kukowska-Latallo et al, 1996). Dendrimers 
increased and prolonged D N A uptake into cells and the nucleus 
(Kukowska-Latallo et al, 1996) through energy-dependent en-
docytosis, which allowed high transfection efficiency compared 
to naked plasmid D N A alone or lipid-mediated ttansfection. 
Dendrimers also increased the stability of D N A inside the cells 
by protecting D N A from degradation by restriction endonucle-
ases, DNase I, or cellular extracts containing nuclease activity 
(Bielinska et al, 1996, 1997), which is particularly important 
for episomal plasmid persistence in ttansfected cells. Den-
drimers are not immunogenic and do not evoke an antibody re-
sponse when given alone or mixed with adjuvant (Roberts et 
al, 1996; Baker, personal communication). Our studies demon-
strate that Starburst dendrimer can be used to mediate efficient 
in vivo transfer of plasmid D N A into murine cardiac isografts 
and allografts. Dendrimer G 5 E D A dramatically increased the 
efficiency of gene ttansfer by about 1,000-fold (about 1 0 % of 
both myocytes and graft infilttating cells stained by X-Gal com-
pared to less than 0.01% of myocytes only stained after naked 
plasmid D N A ttansfer), and extended ttansgene expression (up 
to at least 28 days compared to less than 14 days for naked plas-
mid D N A ; Qin et al, 1995). The higher level and longer last-
ing expression of vIL-10 by dendrimer G 5 E D A resulted in 
markedly prolonged graft survival as compared to naked plas-
mid D N A . Thus, production of immunosuppressive cytokines 
at higher amounts for longer periods of time in a greater ex-
panse of tissue enhanced the immunosuppressive effect and pro-
longed graft survival further. 
It has been reported that while dendrimers enhanced D N A 
uptake into cells and the nucleus (Bielinska et al, 1996; 
Kukowska-Latallo et al, 1996) and increased the stability of 
D N A inside die cells (Bielinska et al, 1996, 1997), it also in-
hibited the initiation of transcription in vitro from promoters 
for either T7 R N A polymerase or eukaryotic R N A polymerase 
n (Bielinska et al, 1997). Both the enhancing and inhibitory 
effects of the dendrimers are related to the DNA-dendrimer 
charge ratio and the generation of the dendrimers. For exam-
ple, G9EDA, which demonstrated better transfection efficiency 
for many cell lines (Kukowska-Latallo et al, 1996), caused 
greater inhibition of T7 polymerase transcription activity than 
G 5 E D A (Bielinska et al, 1997). Lower charge ratios (i.e., 1:10) 
demonsttated higher transfection efficiency, but caused greater 
inhibition of T7 polymerase transcription activity than higher 
charge ratios (i.e., 1:0.1). In addition, this inhibitory effect 
varies for different promoters, since the R N A polymerase II-
dependent transcription from a C M V promoter was affected to 
a lesser degree than T7 R N A polymerase-dependent transcrip-
tion (Bielinska et al, 1997). In this context, the charge ratio of 
D N A to dendrimer and the generation of the dendrimers were 
important determinants for prolongation of allograft survival in 
this model system. The data suggest that several issues, in-
cluding the optimal generation of dendrimer, the DNA-to-den-
drimer charge ratio, and the optimal promoter need to be de-
termined for each model system in vivo and can be manipulated 
to improve gene expression and therapeutic efficacy. 
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